Because SEMA3A mainly binds to these effector and tumor-specific T cells, this inhibitory mechanism is particularly important, and indicate that therapeutic avenues, for example use of antagonistic NRP1 antibodies, could improve anti-tumor immunity. Here, NRP1 is linked to neoplasm.